North America Influenza Diagnostics Market, 2025-2035
The North America Influenza Diagnostics Market is experiencing strong growth driven by advancements in molecular diagnostic technologies, increasing prevalence of influenza, and heightened awareness regarding early detection and disease surveillance. The demand for rapid and accurate diagnostic solutions has surged across hospitals, clinical laboratories, and point-of-care settings. The presence of key players, ongoing product innovations, and favorable regulatory frameworks contribute to a competitive landscape with robust investment in R&D. Forecasts indicate substantial revenue expansion from 2025 onwards, with notable market share changes driven by new technologies and distribution channel modernization.
Latest Market Dynamics
Key Drivers
- Advancements in molecular diagnostics and RT-PCR technologies have increased the accuracy and speed of influenza detection, prompting healthcare systems to adopt these methods widely. In June 2024, Abbott Laboratories launched a new RT-PCR platform, reducing turnaround time significantly.
- Rising influenza incidence and heightened focus on pandemic preparedness have incentivized health authorities to expand testing capacities. BD (Becton, Dickinson and Company) recently rolled out high-throughput influenza diagnostic systems across US diagnostic centers, reinforcing this trend.
Key Trends
- Growing adoption of point-of-care diagnostic devices is simplifying flu testing in remote and resource-limited settings. In July 2024, QuidelOrtho Corporation expanded its point-of-care product pipeline to support decentralized testing models.
- Integration of artificial intelligence (AI) for improved diagnostic interpretation enhances the reliability of influenza testing. Thermo Fisher Scientific announced in August 2024 the incorporation of AI-driven analytics within its diagnostic platforms to reduce false positives and negatives.
Key Opportunities
- Expansion in online distribution channels for influenza test kits increases accessibility for both institutional buyers and consumers. In June 2024, Hologic, Inc. established new partnerships with major online pharmacy networks to enhance test kit reach.
- Partnerships between diagnostic manufacturers and retail pharmacy chains allow wider deployment and faster uptake of advanced testing solutions. Roche entered a multi-state agreement with CVS Health in July 2024, enabling rapid deployment of influenza diagnostics at community-level outlets.
Key Challenges
- Variability in influenza virus strains may reduce test accuracy and require frequent updates to diagnostic tools. DiaSorin S.p.A. launched an updated test panel in August 2024 to address emerging subtypes, demonstrating the sector’s need for ongoing innovation.
- Stringent regulatory requirements extend approval timelines and may slow market entry for novel products. In July 2024, bioMérieux faced delays in launching its integrated influenza testing solutions due to regulatory review extensions.
Key Restraints
- High cost associated with advanced molecular diagnostic platforms restricts uptake in smaller healthcare settings, impacting market penetration. Luminex Corporation reported slower adoption rates among medium-sized labs due to pricing pressures in July 2024.
- Limited reimbursement policies for certain advanced diagnostic tests hinder broader adoption. Meridian Bioscience, Inc. highlighted in June 2024 the challenges experienced by US clinics in securing adequate insurance coverage for new influenza assays.
Market Share (%) of North America Influenza Diagnostics Market by Type, 2025
Rapid Influenza Diagnostic Tests dominate the North American influenza diagnostics market by type, reflecting the increasing demand for quick, actionable results in clinical and point-of-care environments. RT-PCR technology holds a considerable share as well, driven by its high sensitivity and specificity, often preferred in hospital and clinical lab settings. Immunofluorescence assays maintain a stable presence due to their application in specialized laboratories. As the landscape evolves, Rapid Influenza Diagnostic Tests are expected to further increase their market share, driven by greater penetration in ambulatory and retail settings.
Market Share (%) of North America Influenza Diagnostics Market by Application, 2025
In North America, hospitals represent the largest application segment for influenza diagnostics, accounting for a significant portion of the total market demand. Clinical laboratories follow closely, leveraging advanced platforms for high-throughput screening. Point of care settings are rapidly gaining momentum as decentralized testing models become more prevalent. This trend highlights a shift toward rapid, near-patient testing and reflects the dynamic adoption across healthcare delivery settings.
North America Influenza Diagnostics Market Revenue (USD Million), 2020-2035
The North America Influenza Diagnostics Market demonstrates a robust upward trajectory in revenue generation from 2020 to 2035. Starting at approximately $1,150 million in 2021, revenues are set to rise steadily, driven by technological advancements, higher testing volumes, and expansion across new care settings. Projections indicate the market will surpass $2,150 million by 2035. The growth pattern reflects a combination of expanded test accessibility, heightened disease prevalence, and ongoing product innovation.
North America Influenza Diagnostics Market YOY (%) Growth, 2020-2035
The year-on-year (YOY) growth rate for the North America Influenza Diagnostics Market illustrates moderate but consistent expansion. In earlier years, rapid adoption of novel diagnostics drove growth above historical averages, with 2021 posting an 8.5% increase. Growth stabilizes to approximately 6.2% by 2025 and maintains sustainable levels (~4.2%) through 2035, signaling a mature yet resilient market responding to new waves of innovation and public health needs.
North America Influenza Diagnostics Market Share (%) by Region, 2025
The United States is the largest regional market for influenza diagnostics in North America, representing 64% of total market share in 2025, buoyed by a large healthcare infrastructure and robust investment in advanced diagnostics. Canada is the second-largest, with an 18% share, reflecting strong government-led flu surveillance programs. Mexico completes the regional breakdown with an 11% share, driven by improving healthcare access and growing adoption of rapid tests.
Market Share (%) by Key Players in North America Influenza Diagnostics Market, 2025
Major players in the North America Influenza Diagnostics Market include F. Hoffmann-La Roche AG, Abbott Laboratories, QuidelOrtho Corporation, and Thermo Fisher Scientific Inc., together accounting for more than half the market in 2025. Roche leads with 20% share, closely followed by Abbott at 17% and QuidelOrtho at 13%. Smaller shares are held by Hologic, BD, and emerging innovators as competition remains strong, underscoring the market’s consolidated yet dynamic nature.
Market Share (%) by Key Buyers in North America Influenza Diagnostics Market, 2025
Hospitals and diagnostic centers constitute the largest buyer segments in the North America Influenza Diagnostics Market, accounting for a combined 61% share in 2025. Large health systems, clinical laboratory chains, and integrated healthcare networks drive bulk procurement. Retail and online channels are rapidly growing, especially for point-of-care test kits, while academic and research institutions retain a smaller yet significant purchasing role.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 1420 |
| Regions | United States, Canada, Mexico |
| Segments | Rapid Influenza Diagnostic Tests, RT-PCR, Immunofluorescence Assays, Serological Assays, Viral Culture, Others, Hospitals, Clinical Laboratories, Research Institutes, Point of Care, Diagnostic Centers, Others, Direct Tenders, Retail Sales, Online Sales, Distributors, Hospital Pharmacies, Others, Molecular Diagnostics, Immunodiagnostics, Others, Small, Medium, Large |
| Players | F. Hoffmann-La Roche AG, Abbott Laboratories, QuidelOrtho Corporation, Thermo Fisher Scientific Inc., Hologic, Inc., BD (Becton, Dickinson and Company), DiaSorin S.p.A., bioMérieux SA, Luminex Corporation, Meridian Bioscience, Inc., Danaher Corporation, GenMark Diagnostics, Inc., Sekisui Diagnostics, LLC, SA Scientific Ltd., Alere Inc. |
Key Recent Developments
- June 2024: Abbott Laboratories announced the release of a next-generation RT-PCR influenza diagnostic platform aiming to deliver results in under 25 minutes.
- July 2024: QuidelOrtho Corporation expanded its point-of-care influenza testing portfolio launching a CLIA-waived rapid diagnostic kit.
- July 2024: Roche entered a partnership with CVS Health to provide decentralized flu testing solutions across multiple US states.
- August 2024: Thermo Fisher Scientific integrated AI-driven pattern recognition technologies in its leading influenza diagnostic systems to enhance result accuracy.
- August 2024: DiaSorin S.p.A. introduced an updated multiplex influenza panel addressing emerging subtypes, targeting improvement in diagnostic accuracy.
